Full history for every metric is available with a Kvantra account
Astria Therapeutics, Inc. (ATXS)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Operating profit | $m | -112 | -137 | |||||
| Net profit | $m | -26 | -37 | -195 | -52 | -73 | -94 | -124 |
| EPS reported | $ | -1.68 | -2.15 | |||||
| Operating cashflow per share | $ | -1.45 | -1.18 | |||||
| Capex per share | $ | 0.01 | 0.01 | |||||
| FCF per share | $ | -1.45 | -1.19 | |||||
| Free cash flow | $m | -82 | -120 | |||||
| Net debt | $m | -328 | -228 | |||||
| Book value equity | $m | 319 | 233 | |||||
| Book value per share | $ | 5.68 | 4.02 | |||||
| Number of shares | m | 56.16 | 58.01 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.57 | 3.08 | |||||
| P/S LTM | x | 0.00 | 1,017.18 | |||||
| P/FCF LTM | x | -6.16 | -5.97 | |||||
| EV/EBITDA LTM | x | -4.75 | -3.95 | |||||
| EV/Sales LTM | x | 0.00 | 694.63 | |||||
| Earnings Yield LTM | % | -18.77% | -8.87% | |||||
| FCF Yield | % | -16.24% | -16.76% | |||||
| Quality | ||||||||
| ROE | % | -29.52% | -26.20% | |||||
| ROIC | % | -34.37% | -28.00% | |||||
| Operating margin | % | 0.00% | -9904.2% | |||||
| Gross margin | % | 0.00% | 100.00% | |||||
| FCF/Sales | % | - | -9765.3% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -15.23 | -26.98 | |||||
| Net Debt/EBITDA | x | 0.58 | 1.42 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -65.35% | -31.71% | |||||
| Net debt/Equity | x | -1.03 | -0.98 | |||||
| Gross debt/equity | x | 0.02 | 0.02 | |||||
Company overview
Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological disorders across the United States. Its leading experimental drug, STAR-0215, is a monoclonal antibody that targets and inhibits plasma kallikrein. This candidate is presently undergoing preclinical development to address hereditary angioedema. The company adopted its current name, Astria Therapeutics, Inc., in September 2021, having previously operated as Catabasis Pharmaceuticals, Inc.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Astria Therapeutics, Inc. (ATXS)
Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological disorders across the United States. Its leading experimental drug, STAR-0215, is a monoclonal antibody that targets and inhibits plasma kallikrein. This candidate is presently undergoing preclinical development to address hereditary angioedema. The company adopted its current name, Astria Therapeutics, Inc., in September 2021, having previously operated as Catabasis Pharmaceuticals, Inc.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free